Clopidogrel Resistance Is Associated with Thromboembolic Complications in Patients Undergoing Neurovascular Stenting

References

1. 1.↵
   1. Chimowitz MI,
   2. Lynn MJ,
   3. Derdeyn CP,
   4. et al

   . Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993–1003

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Oxley TJ,
   2. Mitchell PJ,
   3. Yan B

   . Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. Front Neurol 2011;2:83

   PubMed
3. 3.↵
   1. Leon MB,
   2. Baim DS,
   3. Popma JJ,
   4. et al

   . A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: stent anticoagulation restenosis study investigators. N Engl J Med 1998;339:1665–71

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Fiorella D

   . Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel. J Neurointerv Surg 2010;2:44–49

   Abstract/FREE Full Text
5. 5.↵
   1. Gurbel PA,
   2. Bliden KP,
   3. Hiatt BL,
   4. et al

   . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13

   Abstract/FREE Full Text
6. 6.↵
   1. Järemo P,
   2. Lindahl TL,
   3. Fransson SG,
   4. et al

   . Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233–38

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Price MJ,
   2. Coleman JL,
   3. Steinhubl SR,
   4. et al

   . Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006;98:681–84

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Bonello L,
   2. Tantry US,
   3. Marcucci R,
   4. et al

   . Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–33

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Pinto Slottow TL,
   2. Bonello L,
   3. Gavini R,
   4. et al

   . Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009;104:525–30

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Lee DH,
    2. AA,
    3. Morsi H,
    4. Shaltoni H,
    5. et al

    . Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389–94

    Abstract/FREE Full Text
11. 11.↵
    1. Müller-Schunk SL,
    2. Peters N,
    3. Spannagl M,
    4. et al

    . Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786–91

    Abstract/FREE Full Text
12. 12.↵
    1. Prabhakaran S,
    2. Wells KR,
    3. Lee VH,
    4. et al

    . Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281–85

    Abstract/FREE Full Text
13. 13.↵
    1. Drazin D,
    2. Choulakian A,
    3. Nuno M,
    4. et al

    . Body weight: A risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J Neurointerv Surg 2011;3:177–81

    Abstract/FREE Full Text
14. 14.↵
    1. Bonello L,
    2. Camoin-Jau L,
    3. Arques S,
    4. et al

    . Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404–11

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Ari H,
    2. Ozkan H,
    3. Karacinar A,
    4. et al

    . The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 2012;157:374–80

    CrossRefPubMed
16. 16.↵
    1. Aradi D,
    2. Rideg O,
    3. Vorobcsuk A,
    4. et al

    . Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest 2012;42:384–92

    CrossRefPubMed
17. 17.↵
    1. van Werkum JW,
    2. Hackeng CM,
    3. Smit JJ,
    4. et al

    . Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2007;49;1505–16
18. 18.↵
    1. Maruyama TH,
    2. Dembo T,
    3. Nagoya H,
    4. et al

    . Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 assay. Int Med 2011;50:695–98

    CrossRef
19. 19.↵
    1. Shim CY,
    2. Yoon SJ,
    3. Park S,
    4. et al

    . The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009;134:351–55

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Angiolillo DJ,
    2. Fernandez-Ortiz A,
    3. Bernardo E,
    4. et al

    . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505–16

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Matetzky S,
    2. Shenkman B,
    3. Guetta V,
    4. et al

    . Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171–75

    Abstract/FREE Full Text
22. 22.↵
    1. Lev EI,
    2. Patel RT,
    3. Maresh KJ,
    4. et al

    . Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27–33

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Shuldiner AR,
    2. O'Connell JR,
    3. Bliden KP,
    4. et al

    . Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–57

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Hochholzer W,
    2. Trenk D,
    3. Fromm MF,
    4. et al

    . Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427–34

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Mega JL,
    2. Hochholzer W,
    3. Frelinger AL,
    4. et al

    . Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221–28

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Breet NJ,
    2. van Werkum JW,
    3. Bouman HJ,
    4. et al

    . High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97;983–90

    Abstract/FREE Full Text
27. 27.↵
    1. Price MJ,
    2. Berger PB,
    3. Teirstein PS,
    4. et al.

    for the GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Diener HC,
    2. Bogousslavsky J,
    3. Brass LM,
    4. et al

    . Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–37

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Wiviott SD,
    2. Braunwald E,
    3. McCabe CH,
    4. et al

    . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15

    CrossRefPubMedWeb of Science